Management of hepatitis C virus genotype 4

Authors

  • AYMAN A ABDO,

    Corresponding author
    1. Liver Unit, University of Calgary, Calgary, Alberta, Canada
      Dr AA Abdo, Gastroenterology Division, College of Medicine, King Saud University, PO Box 2925, Riyadh 11461, Saudi Arabia. Email: abdoayman@hotmail.com
    Search for more papers by this author
  • SAMUEL S LEE

    1. Liver Unit, University of Calgary, Calgary, Alberta, Canada
    Search for more papers by this author

Dr AA Abdo, Gastroenterology Division, College of Medicine, King Saud University, PO Box 2925, Riyadh 11461, Saudi Arabia. Email: abdoayman@hotmail.com

Abstract

Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype 1 and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed.

© 2004 Blackwell Publishing Asia Pty Ltd

Ancillary